

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2021

Commission File Number 001-38370

**CollPlant Biotechnologies Ltd.**  
(Exact name of registrant as specified in its charter)

**4 Oppenheimer St, Weizmann Science Park**  
**Rehovot 7670104, Israel**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

This Form 6-K is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-229163 and 333-248479) and Form F-3 (File No. 333-229486, 333-228054 and 333-238731), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

---

CollPlant Biotechnologies Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as [Exhibit 99.1](#) and is incorporated herein by reference.

---

1

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**COLLPLANT BIOTECHNOLOGIES LTD.**

Date: September 13, 2021

By: /s/ Eran Rotem  
Name: Eran Rotem  
Title: Deputy CEO and Chief Financial Officer

---

2

---

## CollPlant Overview

H.C. Wainwright 23<sup>rd</sup> Annual  
Global Investment Conference

September 2021



## Safe harbor statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based Bioink, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based Bioink, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

# CollPlant – Unlocking the Regenerative Potential of rhCollagen



## Regenerative and Aesthetic Medicine Company

Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better



## Proprietary Plant-based Technology Platform

Only commercially viable solution for mass production of rhCollagen



## Collaboration Agreements with Industry Leaders

- AbbVie (ABBV)- Worldwide exclusive agreement for dermal and soft tissue fillers. Up to \$103mm in payments plus royalties.
- 3D Systems (DDD)- Bioprinted solutions for breast reconstruction treatments



## Well Capitalized

\$48mm in cash and equivalents (June 30, 2021)

3




## Our body is made of collagen

~30% of body's protein content

Main structural protein in the extracellular matrix (e.g. cartilage, bones, tendons, ligaments, skin and vasculature)

Ideal scaffolding molecule for regenerative medicine





# Transgenic tobacco plants


## Expressing 5 human genes



5

ColliPlant  
Pioneering Regenerative Medicine

## Plant-based platform produces human collagen in mass-scale




6

ColliPlant  
Pioneering Regenerative Medicine

## rhCollagen- Ideal building block for tissue and organ transplants used in regenerative medicine

### Clear advantages over tissue-extracted collagen



#### Better bio-functionality

- Accelerates human cell proliferation
- Faster tissue healing



#### Superior homogeneity


- Controlled physical/rheological properties
- Reproducibility
- Transparency (not visible)




#### Improved safety and greater purity

- Non-immunogenic
- Non-allergenic
- No pathogens
- No foreign body response

7




## Product Pipeline



8

## Collagen platform drives diverse opportunities for value creation



9 \* injectable, bioprinted and Regenerative Tissue Matrix

## Dermal/Soft Tissue Fillers





## Dermal fillers market overview



**~2.2 M**

HA procedures  
in 2019 in the US<sup>1</sup>



**>\$6.2B, 7.6% CAGR**


Global dermal filler market,  
2019<sup>2</sup> CAGR 2020-2026<sup>2</sup>



**\$100-\$250/unit**

Cost per syringe<sup>3</sup>

2019 Procedure breakdown, U.S (by material)<sup>1</sup>



11

- <https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf>
- <https://www.gminsights.com/industry-analysis/dermal-filler-market>
- <https://www.medicalspa.com/juvederm-hydrate>, <https://www.medicalspa.com/buy-juvederm-ultra-plus-xc>



## Collaboration agreement with AbbVie (Feb. 2021)

### Agreement highlights:



A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market



Combines CollPlant's proprietary rhCollagen technology and AbbVie's technology



First right of negotiation for technology in an injectable breast implant and photocurable dermal filler

### Financial highlights:



Up to \$103M in potential payments, including:

- \$14M upfront payment
- Up to \$89 milestones and option payments



Royalties on products sales




CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products

12



## rhCollagen-based photocurable regenerative dermal filler key attributes



13

<http://collplant.com/products/photocurable-dermal-filler-animation-video/>



## Injectable breast implants\*

- Composed of rhCollagen, additional materials and fat cells taken from the patient
- Intended to promote breast tissue regeneration
- Designed to support the viability and function of the autologous fat cells, and to attract cells to promote tissue regeneration
- The scaffold is designed to gradually degrade and be replaced by newly grown natural breast tissue that is free of any foreign material



14

\* AbbVie's Option Product



## 3D Bioprinted Tissues and Organs



### A great medical need for supply of life saving organs



**~30,000**

US transplants per year



**115,000**

US waiting list



**900,000**

US deaths per year from  
organ impairment


3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs

The technological building blocks already exist – a system integrator is needed to assemble them all together

CollPlant's rhCollagen-based BioInks portfolio and biomaterials expertise, are ideal for tissue and organ manufacturing



## 3D bioprinting represents a wide range of development opportunities



## rhCollagen BioInk compositions in development



## Breast Reconstruction / Augmentation



### Regenerative Tissue Matrix (RTM) Developed in collaboration with 3D Systems



Provide extra coverage, direct-to-implant reconstruction and superior cosmetic results



US: mostly human-sourced (93%)  
EU: mostly animal-sourced



Used in 61% of U.S. breast reconstruction surgeries




Breast reconstruction procedures using ADMS /yr (US): **60K**



Market potential (US) **\$600Mn**

Surgical matrixes derived from cadavers and animals are associated with high costs, supply shortage and batch-to-batch variability

rhCollagen-based regenerative tissue matrix





## Breast implants market overview

**Current breast reconstruction** is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it.



**\$1.4B Market**  
worldwide (2018)<sup>1</sup>




**\$ 5-10K Cost**  
per full procedure in US<sup>2</sup>



**~2,500,000**  
Breast implant procedures WW (2019)<sup>3</sup>  
**~550,000** in US (2019)<sup>4</sup>




**FDA alert:** Patients with breast implants have an increased risk of developing breast implant Associated-Anaplastic Large Cell Lymphoma (Feb 2019)<sup>5</sup>



1. Analytical Research Cognizance, Global Breast Implant Market, March 2019
2. <https://www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1>
3. <https://www.isaps.org/wp-content/uploads/2020/12/Global-Survey-2019.pdf>
4. <https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf>
5. <https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-letter-health-care-providers>

## CollPlant's 3D bioprinted breast implants



\* ECM- extracellular matrix

## Product pipeline

Product	Next milestone
 Dermal filler (AbbVie)	According to plan
 rhCollagen BioInks	1 <sup>st</sup> BioInk market launch expected Q4, 2021
 Regenerative Tissue Matrix (with DDD)	Preclinical package
 Photocurable dermal filler	Preclinical package
 Injectable breast implant	Preclinical package
 Breast implants (3D printed)	Preclinical package

23



## Experienced management team



**Yehiel Tal**  
CEO  
Regentis Biomaterials  
ProChon Biotech  
Kulicke & Soffa Industries



**Eran Rotem**  
Deputy CEO & CFO  
Tefron, CFO (NYSE, TASE)  
Healthcare Tech., CFO  
(NASDAQ) & Gamida  
E&Y



**Nadav Orr, PhD**  
VP R&D  
Ethicon Biosurgery,  
Johnson & Johnson



**Ilana Belzer, PhD**  
COO  
BioHarvest  
Procognia Ltd.  
Omrix Biopharmaceuticals  
Interpharm



**Philippe Bensimon, PharmD**  
VP RA/QA/CA  
Maquet Getinge  
3M Medical



**Hadas Dreier-Horowitz**  
VP HR  
Elbit  
Teva Pharmaceuticals  
Mul-T-Lock

24





## CollPlant investment thesis



Only commercially viable technology currently available that can produce truly human collagen



Multi-billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics



Broadly applicable technology: Ideal building block/scaffolding molecule for regenerative medicine



Strategic agreement with AbbVie and 3D Systems



Clinically validated technology



Proven management team

25



Thank you



CollPlant  
Biotechnologies

Pioneering  
Regenerative  
Medicine